JUL 18, 2021 3:34 PM PDT

COVID-19 Antibiotic No More Effective than Placebo

WRITTEN BY: Annie Lennon

Azithromycin, a broad-spectrum antibiotic commonly used to prevent symptoms of COVID-19 in non-hospitalized patients, does not prevent COVID-19 symptoms from arising and may even increase a person's chance of hospitalization. The corresponding study was published in JAMA by researchers in California. 

Azithromycin is widely prescribed in the US and the rest of the world as a treatment for COVID-19. It was initially recommended on the basis that its anti-inflammatory properties may help prevent the progression of COVID-19 if used early on in the disease. 

"Most of the trials done so far with azithromycin have focused on hospitalized patients with pretty severe disease," said Catherine Oldenburg, lead author of the study. "Our paper is one of the first placebo-controlled studies showing no role for azithromycin in outpatients."

For the study, researchers recruited 263 people who tested positive for SARS-CoV-2 within seven days of enrolment. None of the patients were hospitalized at the beginning of the study. 

They were split into two treatment groups: the first group of 171 participants received a single, 1.2 gram oral dose of azithromycin, while the second group of 92 participants received an identical placebo. 

By day 14, the researchers found that there was no significant difference in the proportion of participants in either group who were symptom-free. In both groups, 50% of participants had no symptoms. By day 21, while patients given the antibiotic had been hospitalized, the same was true for none of the participants in the placebo group. 

The researchers conclude that their findings do not support the routine use of azithromycin for outpatients SARS-CoV-2 infection. The drug seemingly performs no better than a placebo in preventing COVID-19 symptoms from arising, as well as hospitalization from the disease. 

 

Sources: JAMAEurekAlert

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
NOV 01, 2021
Health & Medicine
How Our Understanding of Cellular Reprogramming May Redefine Transplant Medicine
NOV 01, 2021
How Our Understanding of Cellular Reprogramming May Redefine Transplant Medicine
Liver disease represents a significant public health concern and was diagnosed in roughly 4.5 million adults i ...
NOV 05, 2021
Cannabis Sciences
Advances in Medical Cannabis for Treating Autism Spectrum Disorder
NOV 05, 2021
Advances in Medical Cannabis for Treating Autism Spectrum Disorder
Encouraging clinical evidence has recently sparked an emerging interest in the use of CBD-enriched medical cannabis as a ...
NOV 23, 2021
Health & Medicine
No Short Term Effects of THC-positive Breast Milk
NOV 23, 2021
No Short Term Effects of THC-positive Breast Milk
A recent study found that THC does not have short-term negative effects on an early, premature baby’s health. Rese ...
DEC 06, 2021
Cancer
Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment
DEC 06, 2021
Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment
The most common form of non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). DLBCL is a fast-growing cancer th ...
DEC 27, 2021
Microbiology
Anthrax Toxin Has Potential as Non-Opioid Pain Therapeutic
DEC 27, 2021
Anthrax Toxin Has Potential as Non-Opioid Pain Therapeutic
Anthrax conjures thoughts of bioterrorism, though it's a disease caused by a rare but naturally-occurring bacterium, Bac ...
DEC 30, 2021
Cannabis Sciences
Is Five Afraid of Six? Novel Hexyl Homolog of CBD Exhibits Analgesic Activity in vivo
DEC 30, 2021
Is Five Afraid of Six? Novel Hexyl Homolog of CBD Exhibits Analgesic Activity in vivo
According to a recent study published in Nature’s Scientific Reports, a novel hexyl homolog of cannabidiol (CBD) & ...
Loading Comments...